Metagenomi Therapeutics Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Metagenomi Therapeutics Inc 's ROA in the third quarter of 2026?
Metagenomi Therapeutics Inc recorded a cumulative net loss of $-94 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -50.3%.

However, within the Healthcare sector 567 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 3772, from total ROA ranking in the second quarter of 2026 at 4370.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	-38.29 %	-36.21 %	-33.16 %	-38.54 %	-21.19 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-94	-93	-86	-88	-89
Return On Assets (TTM)	-50.3 %	-44.29 %	-36.45 %	-33.75 %	-30.05 %
MGX's Total Ranking	# 3772	# 4370	# 3813	# 3767	# 3716
Total Assets (TTM) in million	153	174	199	223	248
Seq. Total Assets Change	-11.92 %	-12.76 %	-10.82 %	-9.95 %	-8.94 %
Seq. Net Income Change	-	-	-	-	-

MGX's 5 Years Annual ROA >> Back to MGX Management Effectiveness >> Compare MGX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 79
Sector	# 568
Overall	# 3916

Return On Assets Statistics
High	Average	Low
-21.04 %	-33.5 %	-50.29 %
(Dec 31 2024)

Financial Statements
Metagenomi Therapeutics Inc 's Assets	$ 153 million	MGX's Balance sheet
Metagenomi Therapeutics Inc 's Income	$ -21 million	Quarterly MGX's Income Statement
MGX's Income by Division		See MGX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	FY	FY	FY
Y / Y Total Assets Change	-20.87 %	-	-	-	-
Total Assets in million	223	282	0	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-88	-78	0	0	0
Annual Return On Assets	-39.36 %	-27.67 %	-	-	-

MGX's 5 Years Annual ROA >> Back to MGX Management Effectiveness >> Compare MGX ROA to its Competitors

More Return On Assets Ratios
MGX's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
MGX's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for MGX's Competitors
Subscribers only: Roa for Metagenomi Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for MGX's Customers

You may also want to know
MGX's Roi	MGX's Inventory Turnover Ratio	MGX's Growth Rates	MGX's Dividend Comparisons
	MGX's Profitability Ratios	MGX's Asset Turnover Ratio	MGX's Dividend Growth
MGX's Roe	MGX's Valuation Ratios	MGX's Financial Strength Ratios	MGX's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector

ROA

Date modified: 2026-11-11T13:51:50+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.